 |
answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to
making regulatory decisions in accordance with statutory timeframes. The MHRA has
recently undertaken a significant recruitment exercise to bring on board new specialist
staff to increase clinical trial assessor capacity within the Agency. The MHRA are
supplementing this new assessor capacity with additional fixed-term resource of appropriately
experienced and qualified specialists to support the training and supervision of new
staff.</p><p>The MHRA continue to develop plans to increase staff capability and expertise,
and to review internal processes for efficiencies. To that end, significant progress
has been made to draft proposals for how a risk-proportionate approach to clinical
trial assessments could be implemented.</p><p>Following public consultation, the MHRA
plans to reform national legislation to deliver a world-class sovereign regulatory
environment for clinical trials that will support the development of innovative medicines
and ensure that the UK retains and grows its reputation as a world leading base for
life sciences.</p>
|
|
